DOCSLIB.ORG

(15) Sr No Student Name Program Graduated

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(15) Sr No Student Name Program Graduated 5.2.2 Average percentage of placement of outgoing students during the last five years (15) Package in Download Sr No Student Name Program graduated from Name of Employer Lac. Proof 1 Akansha Agrawal B.A., LL.B. (Hons.) Juris Consultant 500000 Click Here 2 Desai Sagar Jayulkumar B.A., LL.B. (Hons.) Hester Bioscience Ltd 500000 Click Here 3 Jhaveri Kahini Monish B.A., LL.B. (Hons.) LegalWiz.in 500000 Click Here 4 Himani Sharma B.A., LL.B. (Hons.) PWC 500000 Click Here 5 Archika Gupta B.A., LL.B. (Hons.) Quislex Legal Services Pvt. Ltd. 500000 Click Here 6 Dhwani Joshi B.A., LL.B. (Hons.) ILNU Nirma University 480000 Click Here 7 Anmary Varghese B.A., LL.B. (Hons.) Tata Institute of Social Science 500000 Click Here 8 Aditya Bishan Mahadevia B. Com., LL.B. (Hons.) Literati Juris 500000 Click Here 9 Shah Nupur Anilbhai B. Com., LL.B. (Hons.) Self Employed 500000 Click Here 10 Ankit Jethwani B. Com., LL.B. (Hons.) S.K. SINGHI & Co - India 500000 Click Here 11 Khorakiwala Fatema Joherbhai B. Com., LL.B. (Hons.) Wadia Gandhy 500000 Click Here M. Tech in Instrumentation and Control 12 Rishabh Parmar Cognizant 330000 Click Here Engineering (Control and Automation) M. Tech in Instrumentation and Control 13 Ardeshana Madhuree A Infosys 330000 Click Here Engineering (Control and Automation) M. Tech in Instrumentation and Control 14 Vhora Hasan Jujar Infosys 330000 Click Here Engineering (Control and Automation) M. Tech in Instrumentation and Control 15 Shaival Hemant Nagarsheth Tata Consultancy Services 330000 Click Here Engineering (Control and Automation) M. Tech in Instrumentation and Control 16 Dhananjay Panpalia Tata Consultancy Services 330000 Click Here Engineering (Control and Automation) 17 ABHYANKAR AMIT SANJAY M. Tech. in Mechanical Engineering (CAD/CAM) Cognizant 330000 Click Here 18 BODANA KRUSHNARAJSINH NARENDRASINH M. Tech. in Mechanical Engineering (CAD/CAM) Tata Consultancy Services 330000 Click Here 19 PATEL KRUNAL JAGADISHBHAI M. Tech. in Mechanical Engineering (CAD/CAM) Tata Consultancy Services 330000 Click Here 20 PATEL NIKHIL BHARATKUMAR M. Tech. in Mechanical Engineering (CAD/CAM) Tata Consultancy Services 330000 Click Here M. Tech in Civil Engineering (Computer Aided 21 Husain Mohammedi Rangwala Nirma University, Ahmedabad 360000 Click Here Structural Analysis and Design) 22 Desai Brijesh Pravinkumar B. Tech (Chemical Engineering) Adani Ports & SEZ 430000 Click Here 23 Rahul Prannath Gaur B. Tech (Chemical Engineering) Aakash Insitute 550000 Click Here 24 Abhishek Omprakash Gautam B. Tech (Chemical Engineering) Aakash Insitute 550000 Click Here 25 Chandni Sumedh Dholakia B. Tech (Chemical Engineering) Cargill 380000 Click Here Package in Download Sr No Student Name Program graduated from Name of Employer Lac. Proof 26 Diksha Sureka B. Tech (Chemical Engineering) Cargill 380000 Click Here 27 BIRENDRAKUMAR SHRIKANT TIWARI B. Tech (Chemical Engineering) DCM Shreeram 390000 Click Here 28 Ms. Neha Jain B. Tech (Chemical Engineering) DCM Shreeram 390000 Click Here 29 Mahendra Singh B. Tech (Chemical Engineering) Deepak Nitrite 450000 Click Here 30 Poonam Sharma B. Tech (Chemical Engineering) Hindustan Uniliver Limited 700000 Click Here 31 Shalini Saraswat B. Tech (Chemical Engineering) Hindustan Uniliver Limited 700000 Click Here 32 Patel Dhruvinkumar chimanbhai B. Tech (Chemical Engineering) Hindustan Uniliver Limited 700000 Click Here 33 Vanila Mehta B. Tech (Chemical Engineering) Jubilant 550000 Click Here 34 Himanshu Rajendrabhai Bhutia B. Tech (Chemical Engineering) Jubilant 550000 Click Here 35 DHADUK KINTUL DHIRUBHAI B. Tech (Chemical Engineering) Nirma Limited 240000 Click Here 36 VAGADIYA SAGAR JAYANTILAL B. Tech (Chemical Engineering) Quanta Process Solutions Pvt Ltd 240000 Click Here 37 DIVYAKANT BHUPATRAI JOSHI B. Tech (Chemical Engineering) Quanta Process Solutions Pvt Ltd 240000 Click Here 38 Patel Kaushal Ambalal B. Tech (Chemical Engineering) Reliance Industries Ltd 550000 Click Here 39 PRAJAPATI SWAPNIL ANIL B. Tech (Chemical Engineering) Reliance Industries Ltd 550000 Click Here 40 Chaudhary Pratikkumar Sudhirbhai B. Tech (Chemical Engineering) Reliance Industries Ltd 550000 Click Here 41 Pooja Pankajbhai Patel B. Tech (Chemical Engineering) Reliance Industries Ltd 550000 Click Here 42 Nilesh Rameshwar Jakher B. Tech (Chemical Engineering) Reliance Industries Ltd 550000 Click Here 43 Rutvi Vithalani B. Tech (Chemical Engineering) Reliance Industries Ltd 550000 Click Here 44 Raktim Ranjan Dutta B. Tech (Chemical Engineering) Tata Chemicals Ltd. 300000 Click Here 45 SHARMISHTHA SHIL B. Tech (Chemical Engineering) Tata Chemicals Ltd. 300000 Click Here 46 Sachania Hitanshu M B. Tech (Chemical Engineering) Tata Chemicals Ltd. 300000 Click Here 47 Rahul Godara B. Tech (Chemical Engineering) Tata Consultancy Services 330000 Click Here 48 Mohammadtakki A Rasbharya B. Tech (Chemical Engineering) Tata Consultancy Services 330000 Click Here 49 PRATIK SINGH B. Tech (Chemical Engineering) Torrent Pharmaceuticals Ltd. 288000 Click Here 50 Patel Dhruvin Rameshbhai B. Tech (Chemical Engineering) Torrent Pharmaceuticals Ltd. 288000 Click Here 51 Anupam Upadhayay B. Tech (Civil Engineering) Aakash Insitute 550000 Click Here 52 AMAN AGRAWAL B. Tech (Civil Engineering) Future FIrst Info Services 720000 Click Here 53 Abhishek sanklecha B. Tech (Civil Engineering) Infosys 330000 Click Here 54 PARYANT SHAH B. Tech (Civil Engineering) Infosys 330000 Click Here 55 Monika Chaudhary B. Tech (Civil Engineering) Infosys 330000 Click Here 56 Doshi Smit Rajendra B. Tech (Civil Engineering) Infosys 330000 Click Here 57 MIHIRSINH P. DESAI B. Tech (Civil Engineering) L & T 460000 Click Here 58 Raval Harshkumar Maheshbhai B. Tech (Civil Engineering) L & T 460000 Click Here 59 MEHTA YASH MAHAVIR B. Tech (Civil Engineering) L & T 460000 Click Here 60 akash mehta B. Tech (Civil Engineering) L & T 460000 Click Here 61 ABHINAV CHOUDHARY B. Tech (Civil Engineering) MU Sigma 400000 Click Here Package in Download Sr No Student Name Program graduated from Name of Employer Lac. Proof 62 Ankit khindawat B. Tech (Civil Engineering) Nirma Limited 240000 Click Here 63 Babariya Vipul P. B. Tech (Civil Engineering) Nirma Limited 240000 Click Here 64 DARJI MEHULKUMAR HASMUKHBHAI B. Tech (Civil Engineering) Nirma Limited 240000 Click Here 65 SAGAR RADADIYA B. Tech (Civil Engineering) Nirma Limited 240000 Click Here 66 Ayush arora B. Tech (Civil Engineering) Tata Consultancy Services 330000 Click Here 67 Tejas Jadhav B. Tech (Civil Engineering) Tata Consultancy Services 330000 Click Here Thyssenkrupp Insustrial Solutions India 68 Vaibhav Chitalia B. Tech (Civil Engineering) 460000 Click Here Pvt.Ltd. M. Tech in Electronics and Communication 69 Roshni Mishra Cognizant 330000 Click Here Engineering (Communication Engineering) M. Tech in Electronics and Communication 70 Swati Sharma Cognizant 330000 Click Here Engineering (Communication Engineering) M. Tech in Electronics and Communication 71 Joshi Darshak Amrutlal Infosys 330000 Click Here Engineering (Communication Engineering) M. Tech in Electronics and Communication 72 Vishwa Kelaiya Infosys 330000 Click Here Engineering (Communication Engineering) M. Tech in Electronics and Communication 73 Priyanka Jain Tata Consultancy Services 330000 Click Here Engineering (Communication Engineering) M. Tech in Electronics and Communication 74 Parth Sharma Tata Consultancy Services 330000 Click Here Engineering (Communication Engineering) 75 Aalap Parikh B. Tech (Computer Science and Engineering) Cognizant 330000 Click Here 76 Mohit Bhat B. Tech (Computer Science and Engineering) Cognizant 330000 Click Here 77 DEEPAK SURANA B. Tech (Computer Science and Engineering) Cognizant 330000 Click Here 78 Dhrushit Raval B. Tech (Computer Science and Engineering) Cognizant 330000 Click Here 79 DOMADIA KENIL B. Tech (Computer Science and Engineering) Cognizant 330000 Click Here 80 Gandhi Krunal Anilbhai B. Tech (Computer Science and Engineering) Cognizant 330000 Click Here 81 Jaineel Vyas B. Tech (Computer Science and Engineering) Cognizant 330000 Click Here 82 Jariwala Rohan Jayvadan B. Tech (Computer Science and Engineering) Cognizant 330000 Click Here 83 Manit Ankhad B. Tech (Computer Science and Engineering) Cognizant 330000 Click Here 84 MEHTA MILAN KAUSHIK B. Tech (Computer Science and Engineering) Cognizant 330000 Click Here 85 Mundra Shubham Anil B. Tech (Computer Science and Engineering) Cognizant 330000 Click Here 86 Nidhi Vora B. Tech (Computer Science and Engineering) Cognizant 330000 Click Here 87 PRATIK CHAUHAN B. Tech (Computer Science and Engineering) Cognizant 330000 Click Here 88 Shihora Parth Ashokkumar B. Tech (Computer Science and Engineering) Cognizant 330000 Click Here 89 Shubham Rathi B. Tech (Computer Science and Engineering) Cognizant 330000 Click Here 90 SURABHI SHARMA B. Tech (Computer Science and Engineering) Cognizant 330000 Click Here Package in Download Sr No Student Name Program graduated from Name of Employer Lac. Proof 91 SURBHI ORA B. Tech (Computer Science and Engineering) Cognizant 330000 Click Here 92 Tapan Halani B. Tech (Computer Science and Engineering) Cognizant 330000 Click Here 93 anmol dani B. Tech (Computer Science and Engineering) Cognizant 330000 Click Here 94 Jambudia Amee Ashokkumar B. Tech (Computer Science and Engineering) Cognizant 330000 Click Here 95 Shah Shaili Sunilbhai B. Tech (Computer Science and Engineering) Cognizant 330000 Click Here 96 Rathod Rahul Narsangbhai B. Tech (Computer Science and Engineering) Cognizant 330000 Click Here 97 Hingol Krunal Vinodbhai
Load more

Recommended publications
  • SANJEEVAK 1586083 01/08/2007 MANOJ ANANT JOSHI Trading As ;AKSHAY PHARMA REMEDIES KAVRANA HOUSE, OPP
    Trade Marks Journal No: 1836 , 12/02/2018 Class 5 SANJEEVAK 1586083 01/08/2007 MANOJ ANANT JOSHI trading as ;AKSHAY PHARMA REMEDIES KAVRANA HOUSE, OPP. COTTON GREEN RLY. STN. MUMBAI-400033. MANUFACTURE & MERCHANT INDIAN NATIONAL Used Since :31/01/2001 MUMBAI MEDICINAL PREPARATIONS. 537 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 SEPTIGARD 1741718 08/10/2008 INDERJIT SINGH trading as ;INDERJIT SINGH B-104 , SWASTHYA SINGH , NEW DELHI -92 MERCHANTS & MANUFACTUERERS Address for service in India/Agents address: MAHTTA & CO. 43 - B/3, MAHTTA HOUSE,UDHAM SINGH NAGAR, LUDHIANA - 141 001, (PUNJAB). Proposed to be Used DELHI MEDICINAL & PHARMACEUTICAL PREPARATIONS. 538 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 FAIR & BEAUTY 1803779 08/04/2009 GALPHA LABORATORIES LIMITED 221, Kanakia Zillion, E Wing Bandra Kurla Complex Annex LBS Marg & CST Road Junction Kurla West MUMBAI 400070 MANUFACTURERS AND MERCHANTS INDIAN NATIONAL Used Since :15/11/2007 MUMBAI PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES 539 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 O-BAMA 1815900 08/05/2009 KREMOINT PHARMA PVT. LTD. 151/5, SHRI KRISHNA DARSHAN, GARODIA NAGAR, GHATKOPAR (E), BOMBAY-400 077. MANUFACTURERS AND MERCHANTS. A CORPORATE ENTITY INCORPORATED IN INDIA UNDER THE COMPANIES ACT 1956. Address for service in India/Attorney address: KRISLAW CONSULTANTS BUILDING NO.4, C/104, SHANKESHWAR PALMS, BEHIND MODEL SCHOOL, KUMBHARKHANPADA, SUBHASH ROAD, DOMBIVILI(W) 421202 Used Since :02/05/2009 MUMBAI PHARMACETICAL AND MEDICINAL PREPARATIONS. 540 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 AYUSHAKTI D-VYRO 1815928 08/05/2009 SMITA NARAM BUNGALOW NO.31, NEXT TO M.
    [Show full text]
  • Daiichi Sankyo Move Could Spark Copycats
    June 12, 2008 Daiichi Sankyo move could spark copycats Lisa Urquhart Daiichi Sankyo’s surprise move yesterday on Ranbaxy sparked not only a flurry of news about the $4.1bn deal, but has also got many in the market wondering who else might be on the shopping list of other big pharma companies looking to snap up an Indian generics firm. Those excited by the acquisition are pointing to the attractions of these companies, which include the increasing moves by governments to use generics to reduce healthcare costs, and in the case of Indian generic companies, their access to the fast growing, developing markets that big pharma has already expressed an interest in. With Ranbaxy now out of the picture, according to the EvaluatePharma’s Peer Group Analyzer Glenmark would be one of the most attractive in terms of future growth. The company may not be in the top three of the biggest Indian generics, but it is forecast to report an impressive 38% compound annual growth in unbranded generic sales in the five years to 2012. WW Unbranded Generic Sales WW annual sales ($m) CAGR (07-12) Market Rank 2007 2012 2007 2012 Glenmark Pharmaceuticals 244 1,211 38% 30 16 Wockhardt 357 764 16% 25 20 Lupin 303 647 16% 27 26 Aurobindo Pharma 165 334 15% 31 31 Matrix Laboratories 131 265 15% 34 35 Cipla 872 1,656 14% 14 11 Ranbaxy Laboratories 1,496 2,827 14% 9 6 Torrent Pharmaceuticals 300 543 13% 28 29 Piramal Healthcare 418 756 13% 20 21 Zydus Cadila 395 697 12% 22 24 Sun Pharmaceutical Industries 775 1,332 11% 15 15 Dr.
    [Show full text]
  • Hy Sun Missed the Pharma Rally: the Answer Is Hidden in a Bet Many Failed — Speciality Drugs - the Economic Times
    12/3/2020 Sun Pharma: Why Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs - The Economic Times Home ETPrime Markets News Industry RISE Politics Wealth MF Tech Jobs Opinion NRI Panache ET NOW More Aayush English Edition | E-Paper Tech Consumer Markets Corporate Governance Telecom + OTT Auto + Aviation Pharma Fintech + BFSI Economy Infra Environment Energy Business News › Prime › Pharma › Why Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs Getty Images MARKETS hy Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs Dilip Shanghvi, founder and managing director, Sun Pharmaceuticals Synopsis Sun Pharma is the only Indian company to have made some inroads into speciality drugs. What worries investors is high investments and uncertainties over ramp up in revenue. The stock can still see upside because of its current valuations, strong India business, and any positive surprises in US generic business. But it is crucial that its speciality bet pays off. BACK TO TOP https://economictimes.indiatimes.com/prime/pharma-and-healthcare/why-sun-missed-the-pharma-rally-the-answer-is-hidden-in-a-bet-many-failed-spe… 1/11 12/3/2020 Sun Pharma: Why Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs - The Economic Times Home ETPrime Markets NeCwasllI nitd uas trbyleRssISiEngP oilniti cdsisWgeuailthse fMoFr tTheceh InJodbisanOpinion NRI Panache ET NOW More pharmaceutical industry. The stocks of pharma companies have been on a tear since the beginning of the Covid-19 crisis.
    [Show full text]
  • Pharmaceuticals Stellar Quarter; Healthy Outlook Sector Update
    Pharmaceuticals Stellar quarter; Healthy Outlook Sector Update Q2FY2021 was yet another stellar quarter for pharmaceutical companies under Q2FY2021 Results Review Sharekhan’s pharma universe. The quarter witnessed a sustained improvement in Sector: Pharmaceuticals the US business while the domestic business showed signs of improvement. The overall plant utilization levels during Q2FY2021 were at normal levels (as against Sector View: Positive relatively low utilization levels in previous quarter), thus yielding costs benefits. For the quarter, the pharma companies delivered revenue growth of 8.8% y-o-y, while sequentially as well it clocked a growth of 8.3%. Topline performance was better than estimates and was driven by sturdy performance of the US business, while the India operations also grew a decent pace. Growth in the base business, stabilizing price erosion and new launches led to the growth in US business, while in India business, companies with a relatively higher share of chronic business grew strongly and outperformed the industry. Select players such as Aurobindo, Cadila and Cipla reported strong 12.5%, 18% and 10% y-o-y growth respectively in the US business. Divis labs also reported a strong 21% y-o-y growth in the topline backed by a strong performance in the API segment, while Laurus labs posted a 60% revenue Our active coverage universe growth on the back of an impressive growth in the formulations segment. Operating CMP PT profit for the universe increased sharply by 21% y-o-y. Operating margin also Companies Reco. (Rs) (Rs) expanded by 251 bps y-o-y, better the expected 150 bps y-o-y expansion.
    [Show full text]
  • ANNUAL REPORT 2018-19 2 Notice
    CONTENTS Corporate Information ............................................................................................................ 02 Notice .................................................................................................................................... 03 Directors’ Report .................................................................................................................... 14 Annexures to Directors’ Report .............................................................................................. 25 Management Discussion and Analysis .................................................................................. 53 Business Responsibility Report ............................................................................................. 69 Report on Corporate Governance ......................................................................................... 80 Standalone Financial Statements .......................................................................................... 99 Consolidated Financial Statements ....................................................................................... 154 Financial Highlights - 5 years ................................................................................................. 212 CORPORATE INFORMATION BOARD OF DIRECTORS STATUTORY AUDITORS 1. Shri Sudhir Mehta B S R & Co. LLP Chairman Emeritus Chartered Accountants 2. Shri Samir Mehta Executive Chairman REGISTERED OFFICE 3. Shri Shailesh Haribhakti Torrent House, 4. Shri Haigreve
    [Show full text]
  • Annual Return
    FORM NO. MGT-7 Annual Return [Pursuant to sub-Section(1) of section 92 of the Companies Act, 2013 and sub-rule (1) of (other than OPCs and Small rule 11of the Companies (Management and Companies) Administration) Rules, 2014] Form language English Hindi Refer the instruction kit for filing the form. I. REGISTRATION AND OTHER DETAILS (i) * Corporate Identification Number (CIN) of the company Pre-fill Global Location Number (GLN) of the company * Permanent Account Number (PAN) of the company (ii) (a) Name of the company (b) Registered office address (c) *e-mail ID of the company (d) *Telephone number with STD code (e) Website (iii) Date of Incorporation (iv) Type of the Company Category of the Company Sub-category of the Company (v) Whether company is having share capital Yes No (vi) *Whether shares listed on recognized Stock Exchange(s) Yes No Page 1 of 17 (a) Details of stock exchanges where shares are listed S. No. Stock Exchange Name Code 1 2 (b) CIN of the Registrar and Transfer Agent Pre-fill Name of the Registrar and Transfer Agent Registered office address of the Registrar and Transfer Agents (vii) *Financial year From date 01/04/2020 (DD/MM/YYYY) To date 31/03/2021 (DD/MM/YYYY) (viii) *Whether Annual general meeting (AGM) held Yes No (a) If yes, date of AGM 27/07/2021 (b) Due date of AGM 30/09/2021 (c) Whether any extension for AGM granted Yes No II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY *Number of business activities 1 S.No Main Description of Main Activity group Business Description of Business Activity % of turnover Activity Activity of the group code Code company C C6 III.
    [Show full text]
  • Saturday, 23Rd August 2014 Index Levels : Market Trend (Nifty)
    ` Saturday, 23rd August 2014 Index Levels : Market Trend (Nifty): Trend Reversal Point INDEX SUPPORTS RESISTANCES Period Current Trend (TRP)Nifty close basis NIFTY# 7930/8000/8090 Short Term Trend UP DOWN BELOW 7750 (7913.20) 7850/7760 SENSEX# 26250/26000 26550/26700/27200 Medium Term UP DOWN BELOW 7650 (26419.55) ITE-35* -------- -------- Long Term Trend UP DOWN BELOW 6500 (10239.68) ND #as on 22 August 2014 Imtiaz Merchant’s Best Picks: Indices: CURRENT Domestic COMPANY NAME SIZE SECTOR Close Points % Chg PRICE Indices Large Cipla Health Care 499 BSE Sensex 26419.55 59.44 0.23 % Cap Large Industrials and UPL 338 Nifty 7913.20 22.10 0.28 % Cap Capital Goods ITE Shariah 10239.68 42.83 0.42 % 35* S&P CNX 500 1919.15 4.92 0.12 % Note: (Buying should be done from a medium to long term perspective) Shariah Advance/ Advance Decline AD Un- Market Brief Decline Ratio Changed BSE 1462 1572 0.93:1 114 On the back of positive global cues and some NSE 693 782 0.89:1 60 reform announcements by the Union Shariah Government, the markets on Friday ended the Universe*** 291 269 1.08:1 15 day and the week on positive note; Auto, Info. Technology and Health Care sectors were the flavor of the week. The undertone appears to Global Indices Close Points % Chg be bullish. All the trends are up. More reform Dow Jones* 16979.13 60.36 0.36% announcements from the Govt. and good NASDAQ* 4526.48 5.62 0.12% corporate results will further fuel the rally and FTSE* 6755.48 22.18 0.33% the Nifty is likely to see the 8000 level soon.
    [Show full text]
  • In the United States District Court for the District of New Jersey
    Case 1:19-md-02875-RBK-JS Document 121 Filed 06/17/19 Page 1 of 130 PageID: 1141 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY IN RE: VALSARTAN PRODUCTS LIABILITY LITIGATION No. 1:19-md-2875-RBK Hon. Robert Kugler Hon. Joel Schneider Jury Trial Demanded Consolidated Amended Class Action Complaint CONSOLIDATED AMENDED ECONOMIC LOSS CLASS ACTION COMPLAINT 1. COME NOW, the Consumer and Third Party Payor (“TPP”) Plaintiffs (collectively the “Class Plaintiffs”), who file this Consolidated Amended Economic Loss Class Action Complaint (“Master Class Complaint”)1 against the below-enumerated Defendants. I. INTRODUCTION 2. This case arises from adulterated, misbranded, and unapproved valsartan- containing drugs (“VCDs”) that were designed, manufactured, marketed, distributed, packaged, and sold by Defendants (identified and defined infra at Part II.C-H) in the United States, and which have been and remain the subject of one of the largest ongoing contaminated drug recalls ever in the United States. These VCDs are non-merchantable, and are not of the quality represented by Defendants named herein. 3. Valsartan and its combination therapy with hydrochlorothiazide are the generic versions of the registered listed drugs (“RLDs”) Diovan® (“DIOVAN”) and Diovan HCT® (“DIOVAN HCT”), respectively. Amlodipine-valsartan and its combination therapy with hydrochlorothiazide are the generic versions of the RLDs of Exforge® (“EXFORGE”) and 1 This is one of three master complaints being filed in this multi-district litigation. The filing of three master complaints is to streamline the pleadings and issues for the parties’ mutual convenience only. Consumer Class Plaintiffs do not waive any claims that are not raised herein, or that are asserted in another master complaint.
    [Show full text]
  • Corporate Overview Statutory Reports Financial Statements
    Corporate Overview Statutory Reports Financial Statements Deepak Nitrite Limited | 1 INDEX CORPORATE OVERVIEW On a Golden Pedestal 01 Financial Highlights 03 Building Sustainable Future 04 Our Strength 06 Message from the Founder (Chairman Emeritus) 14 CEO’s Communique (Outgoing CEO) 17 Enhancing Value Brick by Brick 18 From the Desk of Chairman & Managing Director 21 CEO’s Letter 24 CFO’s Communique 27 Board Of Directors 30 Responsive to Challenges with Resilience 34 Building Sustainable Future with Responsible Chemistry 37 Our Team Our Strength 40 Creating Socially Inclusive and Empowered Society 42 Our COVID-19 Initiatives 47 Corporate Information 48 STATUTORY REPORTS Management Discussion and Analysis 50 Notice 66 Directors’ Report 74 Corporate Governance Report 114 FINANCIAL STATEMENTS Standalone Independent Auditor’s Report 135 Balance Sheet 142 Statement of Profit and Loss 143 Cash Flow Statement 144 Statement of Changes in Equity 146 Notes forming part of the Financial Statements 147 Consolidated Independent Auditor’s Report 189 Balance Sheet 196 Statement of Profit and Loss 197 Cash Flow Statement 198 Statement of Changes in Equity 200 Notes forming part of the Financial Statements 201 Forty-Ninth Annual General Meeting Day & Date : Friday, August 7, 2020 Time : 11:30 A.M. Through Video Conferencing/Other Audio Visual Means Cautionary Statement Regarding Forward-Looking Statement This Report may contain certain forward-looking statements relating to the future business, development and economic performance. Such Statements may
    [Show full text]
  • Marketgrader India All-Cap Growth Leaders Index
    Fact Sheet MarketGrader MarketGrader India All-Cap Growth Leaders Index RESEARCH & INDEXES The MarketGrader India All-Cap Growth Leaders Index consists of the 80 most fundamentally sound companies with the best growth prospects in India, whose shares are listed in the country’s national exchanges or in the United States. Its objective is to give investors access to the best companies in the world’s fastest growing large economy without overpaying for their shares. Constituents are selected across all market cap segments and all economic sectors after they have passed rigorous size and liquidity filters. Index Rules Performance Investable Universe CumulativeIndia Growth Leaders Total Return, Jan. 2008 - Jul. 2021 All data as of July 30, 2021 All companies domiciled in India that have 175% received a MarketGrader Score consistently for at least six months, whose shares are 150% listed on the National Stock Exchange, the 125% Bombay Stock Exchange or on U.S. national 100% exchanges. 75% Regulatory Requirements 50% Stocks are ineligible for Index selection if 25% they are included in the ‘Red Flag List,’ 0% maintained and published by the National Securities Depository Limited (NDSL) of India, -25% or on the ‘Breach List,’ maintained by the -50% Central Depository Services (India) Limited 07/30/21 -75% (CDSL), both of which govern foreign own- 12/31/07 12/31/08 12/31/09 12/31/10 12/30/11 12/31/12 12/31/13 12/31/14 12/31/15 12/30/16 12/29/17 12/31/18 12/31/19 12/31/20 ership limits of Indian securities.
    [Show full text]
  • In the United States District Court for the Eastern District of Michigan
    Case 2:10-cv-10656-AC-MKM Document 1 Filed 02/16/10 Page 1 of 11 IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF MICHIGAN ABBOTT LABORATORIES and ) ABBOTT RESPIRATORY LLC, ) ) Plaintiffs, ) ) C.A. No. 2:10-cv-10656 v. ) ) SUN PHARMACEUTICAL INDUSTRIES, LTD. ) and SUN PHARMA GLOBAL FZE, ) ) Defendants. ) COMPLAINT Plaintiffs Abbott Laboratories and Abbott Respiratory LLC (collectively, “Abbott”), by their attorneys, hereby allege as follows: Nature of the Action This is an action for patent infringement of U.S. Patent Nos. 6,080,428 (“the ‘428 patent”) and 6,469,035 (“the ‘035 patent”), arising under the patent laws of the United States, Title 35, United States Code, 35 U.S.C. §§ 271 and 281. This action relates to Abbreviated New Drug Application (“ANDA”) No. 20-0484 filed by Sun Pharma Global FZE (“Sun FZE”) with the U.S. Food and Drug Administration (“FDA”) for approval to market 500 mg and 1000 mg niacin extended-release tablets that are generic versions of the 500 mg and 1000 mg strength versions of Abbott’s highly successful NIASPAN® drug product. Related Actions The present action is related to an identical patent infringement action pending before the United States District Court for the District of Delaware, Abbott Laboratories and Abbott Case 2:10-cv-10656-AC-MKM Document 1 Filed 02/16/10 Page 2 of 11 Respiratory, LLC v. Sun Pharmaceutical Industries, Ltd. and Sun Pharmaceuticals, Inc. (C.A. 10-cv-112) (the “Delaware Sun Action”), pertaining to ANDA No. 20-0484 filed by Sun FZE for approval to market generic versions of Abbott’s 500 mg and 1000 mg strength NIASPAN® tablets.
    [Show full text]
  • INDIA OUTBOUND T&A Consulting Volume 6 Issue 4 3Rd April, 2017
    INDIA OUTBOUND T&A Consulting Volume 6 Issue 4 3rd April, 2017 As the Financial Year comes to an end so has an eventful The trend among Indian pharma firms of “building brands“ quarter. With the liquidity shock of de-monetization having been continued, with Aurobindo Pharma adding to its portfolio of managed and a healthy, albeit counter-intuitive GDP data biosimilars acquired from a Swiss firm and leveraging market (annualised GDP growth at 7.0% for Oct-Dec Qtr) having access across specialized therapeutic segments provided by a established the soundness of macroeconomic fundamentals, the Portugese generics firm. Also active was Piramal Enterprises, high for the current Government came in the form of results for acquiring the drug portfolio of UK-based Mallinckrodt LLC to reach a the Uttar Pradesh elections. The win for the Bhartiya Janata targeted segment across eight European markets. Sun Pharma and Party in U.P. has consolidated its hold at the Centre and across Zydus Cadilla were active in North America, with Zydus acquiring a India. What that means going forward is further stability on US drug firms for a sizeable cheque to bolster its specialty India’s policy front. Case in point has been the Government’s pharmaceuticals segment whilst Sun Pharma acquired a small push in the on-going budget session of Parliament to meet the Canadian drug discovery firm. On the IT front, the bigger boys of Indian July 2017 deadline in implementing the Goods and Services IT were active acquiring assets in Latin America and their preferred market Tax. The outbound investment story nevertheless continues - United States.
    [Show full text]